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Hepatocellular carcinoma (HCC) primarily originates in the liver with hepatic differentiation. 
However, HCCs are not homogenous, and approximately 35% of HCC cases are classified as 
histopathological variants that present distinct pathologic characteristics. In particular, the 
lymphocyte-rich variant is the rarest subtype accounting for less than 1% of HCCs, which is 
not well known to date about molecular features and pathophysiology. Herein, we present a 
case of a patient who was suspected of metastatic liver cancer and confirmed as lymphocyte-
rich HCC pathologically. A 78-year-old woman who underwent a right hemicolectomy for 
colon cancer was referred to our hospital for a newly detected liver mass. We could not make 
a decision because of insufficient evidence for diagnosis from imaging studies. After resection, 
we found that it was a lymphocyte-rich HCC. The pathologic features and prognostic trends of 
this subtype are also discussed. (J Liver Cancer 2021;21:69-75)
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Liver cancer is the fourth leading cause of cancer-related 
deaths worldwide.1 In Korea, liver cancer is ranked sixth in 
terms of incidence and second in terms of cancer-related 
mortality.2,3 Hepatocellular carcinoma (HCC) accounts for 
75-85% of primary liver cancer cases.1 
HCC primarily originates in the liver with hepatic differ-
entiation. However, HCCs are heterogonous in pathogenesis, 
and further studies have been performed to classify the sub-
types of HCC, specifically based on the morphological char-
acteristics of tumor cells.4,5 Primary hepatic tumors that have 
distinct pathologic features are known as HCC variants.6 As 
many as 35% of HCCs can now be classified into histopatho-
logical variants.7-9 According to the latest World Health Or-
ganization (WHO) Classification of Digestive System Tu-
mors, 5th Edition, variants can be classified into subgroups 
based on genomic and molecular analyses, including steato-
hepatitic, clear cell, macrotrabecular-massive, scirrhous, 
chromophobe, fibrolamellar HCC, neutrophil-rich, and 
lymphocyte-rich subtypes.8
In particular, lymphocyte-rich HCC is the rarest subtype. 
Its molecular features have not been characterized yet, and 
pathophysiology is not well known to date.6-8 We present a 
rare case of a patient who was suspected of metastatic liver 
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cancer and confirmed with lymphocyte-rich HCC patho-
logically. As this report is based on protected health infor-




A 78-year-old woman treated for colon cancer at another 
hospital was referred to our hospital for further evaluation of 
abnormal imaging findings. She was diagnosed with colon 
cancer (stage II) 2 years ago. She underwent a right hemico-
lectomy and received adjuvant chemotherapy for 6 months. 
After treatment, there was no evidence of disease during reg-
ular follow-up. However, a hepatic mass was detected on 
computed tomography (CT) performed for surveillance of 
colon cancer recurrence 3 months ago. She did not have any 
other risk factors for HCC, such as alcoholism and metabolic 
disorders. We did not check the serologic test for viral hepa-
titis at the initial evaluation because she was referred from 
another medical center during the follow-up period and had 
no history of hepatitis. As she had been treated for colon 
cancer, liver metastasis of colon cancer was most suspected 
clinically at that time. Dynamic liver magnetic resonance im-
aging (MRI) and positron emission tomography-computed 
tomography (PET-CT) was also performed. Although imag-
ing studies were conducted fully, the differentiation between 
metastasis and primary liver cancer was still unclear. The pa-
tient wanted a second opinion and thus visited our hospital. 
At the initial inspection, she had no specific symptoms or 
abnormal findings on physical examination. On initial labo-
ratory examination, her complete blood count profile re-
vealed a WBC count of 5.33×103/µL, a hemoglobin level of 
12.3 g/µL, and platelet count of 239×103/µL, which were 
within the normal ranges. Liver function tests also showed 
nearly normal results, with a serum bilirubin level of 0.4 mg/
dL, albumin level of 4.8 g/dL, prothrombin time internation-
al normalized ratio of 1.01, aspartate aminotransferase level 
of 44 IU/L, and alanine aminotransferase level of 34 IU/L. 
Serum levels of alpha-fetoprotein (AFP) and protein induced 
by vitamin K absence or antagonist-II (PIVKA-II) were 3.0 
ng/mL (reference range: 0.0-9.0 ng/mL) and 34 mAU/mL 
(reference range: 0-35 mAU/mL), respectively. Considering 
the history of colon cancer, we performed a carcinoembry-
onic antigen (CEA) assessment also, level 3.06 ng/mL (refer-
ence range: 0.0-5.0 ng/mL). 
2. Imaging findings
An abdominal CT scan that detected a hepatic mass first 
revealed a 3.6-cm-sized lobulated mass in segment VII of the 
liver. It showed peripheral rim enhancement in contrast im-
ages (Fig. 1). The background features of the liver parenchy-
A B
Figure 1. Initial computed tomography scan findings. A 3.6 cm sized lobulated mass is observed in segment VII, showing hypodensity compared 
to normal liver tissue in the pre-contrast phase (A) and peripheral rim enhancement in contrast images (B).
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ma were not remarkable. As the CT scan did not involve dy-
namic phase images, it was limited for evaluating the lesion 
precisely. Dynamic liver MRI showed heterogeneous en-
hancement in the arterial phase and wash-out in the portal 
phase. Hyperintensity was observed in T2-weighted images 
(Fig. 2). PET-CT showed FDG uptake in the hepatic mass 
without evidence of any other lesions (Fig. 3).
3. Diagnosis and treatment 
Although there were typical findings for HCC based on 
imaging studies, liver metastasis of colon cancer could not be 
definitively ruled out due to the clinical history. We planned 
surgical resection for diagnosis and treatment. The patient 
underwent a volume-preserving right hemihepatectomy, and 
the tumor was completely resected. Gross findings of the 
specimen exhibited a lobulated round mass (Fig. 4). Hema-
toxylin and eosin (H&E) staining revealed moderately differ-
entiated hepatic tumor cells, which represented trabecular 
patterns of polygonal cells with distinct cell membranes, 
abundant granular eosinophilic cytoplasm, and a higher nu-
clear-cytoplasmic ratio. Moreover, there was an infiltration 
of a large number of lymphocytes, known as the lymphoepi-
thelioma-like pattern (Fig. 5). The immunohistochemical 
staining results suggested that the tumor cells originated in 
the liver, as arginase-1 was positive, while cytokeratin 7 and 
19 (CK7 and CK19) and epithelial membrane antigen (EMA) 
were negative. T-lymphocyte infiltration was demonstrated 
through diffuse staining of the cluster of differentiation 3 and 
8 (CD3 and CD8). Programmed death-ligand 1 (PD-L1) was 
positive with a 90% tumor proportion score. Epstein-Barr 
virus-encoded RNA (EBER) in situ hybridization (ISH) was 
Figure 2. Dynamic liver magnetic resonance imaging findings. The mass is enhanced heterogeneously and also shows peripheral rim 
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negative (Fig. 6). The pathology of the liver parenchyma 
showed mild inflammation and periportal fibrosis. Based on 
the above findings, we made a diagnosis of lymphocyte-rich 
HCC characterized by infiltration of lymphocytes into hepat-
ic tumor cells. As the patient did not undergo a serologic 
screening test for hepatitis, we checked the viral markers of 
hepatitis B and C virus (HBV and HCV) after surgery, and 
she was found positive for anti-HCV antibody and HCV-
RNA. Therefore, she had this risk factor for HCC that was 
detected retrospectively. She recovered well without compli-
cations and was discharged 10 days after surgery.
Figure 4. Macroscopic findings of the specimen from surgical 
resection. It exhibits a 3.5×2.5×2.5 cm sized lobulated mass with a 
thin capsule encapsulating the mass. It contains a small portion of 
peliosis and necrotic change. Portal vein and bile duct invasion are 
not seen. 
A B
Figure 5. Findings on microscopy. Hematoxylin and eosin (H&E) staining showing moderately differentiated hepatic tumor cells and large 
numbers of intra-tumoral infiltration of lymphocytes, which is referred to as a lymphoepithelioma-like pattern (H&E; ×100 [A], ×400 [B]).
Figure 3. Positron emission tomography-computed tomography 
findings. Increased FDG uptake in the liver mass is observed. 
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In this report, we present a very rare case of lymphocyte-
rich HCC, one of the histopathological variants of HCC. As 
mentioned earlier, approximately 35% of HCC cases consist 
of variants. Among these, lymphocyte-rich HCC is the rarest 
subtype, accounting for less than 1% of histopathological 
variants.7,10 To date, 67 cases of lymphocyte-rich HCC have 
been reported.11 It has also been referred to as lymphoepithe-
lioma-like HCC.5,9,10 
Histologic findings of this subtype are characterized by mas-
sive intratumoral infiltration of lymphocytes.4,5,9 In 1998, Wada 
et al.12 reported that it was defined by the presence of more than 
100 tumor-infiltrating lymphocytes in 10 high-power fields. Al-
though lymphocyte infiltration needs to be observed for its di-
agnosis, a unified definition for the density of lymphocytes re-
quired for diagnosis has not been established.11 
Immunohistochemistry generally shows positive findings 
with routine markers of hepatic differentiation, such as argi-
nase and hepatocyte paraffin 1 (HepPar1).4,13 Many studies 
have shown the infiltrates of inflammatory cells composed 
predominantly of CD4- and CD8-positive T-lymphocytes, 
along with scattered germinal centers that contain B cells.4,14,15 
According to several case reviews, most cases of lymphocyte-
rich HCC show negativity for Epstein-Barr virus encoding 
region in situ hybridization (EBER-ISH), in contrast to lym-
phoepithelioma-like carcinoma originating in the nasophar-
ynx.14,16 A recent study that investigated the expression of 
PD-L1 in HCC demonstrated that lymphocyte-rich HCC 
correlated with high expression of PD-L1.17
Figure 6. Findings on microscopy. Immunohistochemistry showing weakly positive arginase-1 (original magnification, ×200) (A). The cluster of 
differentiation 3 and 8 (CD3 and CD8) showing diffusely positive T-lymphocyte markers (original magnification, ×100) (B, showing the result of 
CD8). Programmed death-ligand 1 is positive with 90% of tumor proportion score (original magnification, ×200) (C). Negative findings of Epstein-
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The clinical outcomes and prognosis of lymphocyte-rich 
HCC are more favorable than those of conventional HCC.12,14 
Lymphocyte-rich HCC showed better overall survival (5-year 
survival, 94.1% vs. 63.9%; P<0.05) and progression-free sur-
vival (5-year survival 87.8% vs. 46.6%, P<0.05) compared to 
HCC without lymphocyte infiltration.14 The reason is not 
fully understood, but it may be due to the immunosuppres-
sive effect of inflammatory cells that control tumor progres-
sion.18 Which contradicts the fact that PD-L1 is generally as-
sociated with poor prognosis in malignancy.17 As there are 
not enough reported cases of this subtype to define the prog-
nostic significance, further research is needed to clarify this 
question. 
Genetic characterization of lymphocyte-rich HCC remains 
largely unknown. Recently, a study has defined the genomic 
landscape of 12 lymphocyte-rich HCCs using whole-exome 
sequencing.19 According to this, mutations in CTNNB1 , 
AXIN1, APC, NOTCH1, and NOTCH2 were less frequently 
observed in lymphocyte-rich HCC than in conventional 
HCC. They also established that the amplification of onco-
genes (CCND1 , FGF19 , and FGF4 ) from chromosome 
11q13.3 was prevalent in lymphocyte-rich HCC, which was 
associated with high immune cell infiltrates and increased 
checkpoint gene expression. These molecular alterations sug-
gest that lymphocyte-rich HCC is possibly more susceptible 
to immunotherapies.19,20
In the present case, it was challenging to make an accurate 
diagnosis using imaging studies alone because the patient 
had been already diagnosed and treated for colon cancer, and 
imaging findings could not completely differentiate between 
primary liver cancer and liver metastasis. Besides, we did not 
detect that the patient had hepatitis C infection as a risk fac-
tor for HCC before surgery. As she was followed up regularly 
for colon cancer, HCC was found at an early stage when it 
could be totally resected and did not need adjuvant treat-
ment. This case also showed the pathologic features de-
scribed above, which included massive infiltration of T-lym-
phocytes, high expression of PD-L1, and negative findings of 
EBER-ISH. 
In conclusion, we encountered a case of lymphocyte-rich 
HCC, which is the rarest histopathological variant of HCC. 
We hope that this case broadens our knowledge of rare HCC 
variants.
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